NRD
RXST icon

Nebula Research & Development’s RxSight RXST Stock Holding History

Nebula Research & Development’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,048
Closed -$781K – 718
2025
Q2 		$781K Hold
60,048
– – 0.07% 492
2025
Q1 		$1.52M Buy
60,048
+16,847
+39% +$501K 0.14% 244
2024
Q4 		$1.49M Buy
43,201
+6,778
+19% +$306K 0.17% 176
2024
Q3 		$1.8M Buy
36,423
+8,471
+30% +$434K 0.22% 110
2024
Q2 		$1.68M Buy
27,952
+11,175
+67% +$639K 0.27% 94
2024
Q1 		$865K Buy
16,777
+9,270
+123% +$455K 0.19% 181
2023
Q4 		$303K Buy
+7,507
New +$220K 0.09% 436

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nebula Research & Development's RXST Position: Q3 2025 in Review

Nebula Research & Development sold out of RxSight (RXST) in Q3 2025, closing a stake of 60,048 shares — an estimated $781K sold.

Nebula Research & Development first reported a position in RXST in Q4 2023 and held it in 7 quarters. The position peaked at $1.8M in Q3 2024. 160 funds tracked by Wall St. Rank hold RXST as of Q3 2025.

  • Nebula Research & Development reported no remaining RxSight position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 60,048 RxSight shares in Q3 2025, an estimated $781K.
  • Nebula Research & Development first reported a position in RxSight in Q4 2023 and held it in 7 quarters.
  • Nebula Research & Development's RxSight position peaked at $1.8M in Q3 2024.
  • 160 funds tracked by Wall St. Rank held RxSight as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.